Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver ...

Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC ...

The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.

The key element of the agreement is confirmation that UK pharmaceutical exports to the US will face a preferential tariff ...

Regene Therapeutics has received RMAT designation from the US FDA for its lead product, NouvNeu001, aimed at treating PD.

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Bristol Myers Squibb (BMS) has entered into an agreement with Microsoft to advance AI-driven early lung cancer detection.